免费看裸体 视频阳春-免费看裸体 网水视频-免费看裸体 网站-免费看裸体 网站视频-免费看裸体 网站涂抹-免费看裸体 阳春

Cell Therapy
Universal Cell Platform
Quikin CAR-T Platform
Enhanced T Cell Platforms

Quikin CAR-T Platform


The Quikin CAR-T Platform (Quikin CART) generates T cell products with gene knockout and stable integration of CAR cassette in one step through CRISPR gene editing technology. As a new generation of CAR-T platform, it has several advantages, including simplified manufacturing process, shortened preparation time, higher product uniformity and avoiding the risk of tumorigenesis caused by random integration. The product with integration of anti-CD19 CAR cassette into PD1?locus combines PD1 immune checkpoint inhibition with CART anti-tumor activity. This platform has the potential to prepare enhanced CAR-T cells with gene knockout of multiple immune checkpoints, rapidly produce universal CAR-T cells and prepare dynamically regulated CAR-T cells with high safety, thus providing strong technical support for future improvement of CAR-T cells.


The development of the era of gene therapy

In 2023, the world's first all human targeted BCMA CAR-T therapy "FUCASO" (Equecabtagene Autoleucel) was approved for sale in China for the treatment of recurrent or refractory multiple myeloma (R/R MM)
In 2022, Cilta cel, the first CAR-T cell therapy for the treatment of r/r MM in China, was approved by the FDA for marketing
In 2021, China's first CAR-T product, Aquilensai injection, was approved for marketing by the Chinese NMPA for post-treatment relapsed or refractory diffuse large B-cell lymphoma (DLBCL)
In 2020，CRISPR/Cas9 gene editing technology wins Nobel Prize in Chemistry
In June 2019, zynteglo, the world's first gene therapy drug ,was approved for marketing by the EU EMA for the treatment of thalassemia
In May 2019, Zolgensma, the world's first gene therapy drug,was approved for marketing by the FDA for the treatment of SMA
In 2018, the first CRISPR/Cas9-based in vivo gene therapy clinical trial (EDIT-101) was approved by the FDA for the treatment of Leber Congenital Amaurosis Type 10 (LCA)
In 2017, Kymriah, the world's first CAR-T product, received FDA approval to market for the treatment of relapsed or refractory acute lymphoblastic leukemia (ALL)
In 2016, the first generation of single-base editors were developed
In November 2013, the third generation gene editing technology CRISPR/Cas9 (clustered regularly spaced short palindromic repeats) was introduced
In 2012, Glybera, the world's first AAV gene therapy drug, was approved for marketing by the EU EMA for the treatment of lipoprotein lipase deficiency (LPLD)
In 2010, TALENs (transcription activation-like effector nucleases), a second-generation gene editing technology, was introduced
In 2003, Gendicine, the world's first gene therapy drug, was approved for marketing by the NMPA in China for the treatment of head and neck squamous cell carcinoma (HNSCC)
In 2001, the first generation of gene editing technology ZFNs (zinc finger nucleases) was introduced
In 1990, the world's first clinical trial of gene therapy was approved by the FDA for the treatment of adenosine deaminase deficiency (ADA-SCID)
Back to top
主站蜘蛛池模板： 午夜精品久久久久久久久久久久久久 | 最好看的无码专区_最新的无码专区_最好最新高清无码专区_成人在线观看免费无 | 99热精品在线 | 无码午夜精品一区二区三区视频 | 亚洲午夜精品网络视频 | 色欲AⅤ蜜臀aV在线播放小说 | 午夜精品久久久久久久无码软件 | 少妇无码| 蜜臀AV色欲 | 国产激情高潮流白浆免费视频 | 精品人妻无码一区二区三级精东 | XXX国产熟妇精品ⅩXX | 丰满少妇乱子伦精品看片 | 亚洲午夜AV| 日本wwwcom| 国产真实乱婬A片三区高清蜜臀 | 亚洲av影院 | 91人妻人人澡人人爽人人精品 | 99re这里只有精品99 | 狠狠操狠狠干 | 2025精品国一区视频 | 国产成人成人A片在线乱码软件 | 国产成人片 | 久久中文字幕视频 | 天美MV传媒 | 成人3D动漫一区二区三区在线观看 | 2025国产精品高清在线 | 2025最新毛片免费观看 | 亚洲精品乱码一品二品三品欧美 | 日韩在线视频一区二区三区四区蜜桃 | 免费无码专区 | 国产成人成人A片在线乱码软件 | 亚洲精品久久久久久久蜜桃 | 97无码欧美熟妇人妻蜜桃天美 | 久久婷婷婬片A片AAA | 粉嫩av浪潮av蜜臀人妻 | 五十路熟妇无码AV在线 | 日韩综合网 | 麻豆天美久久 | 91香蕉国产 | 亚洲AV无码成人精品区欧洲 |